Table of Contents
Understanding Abilify Maintena:
Abilify Maintena, an extended-release injection containing aripiprazole, is utilized either independently or in conjunction with other aripiprazole formulations to address schizophrenia, a mental disorder characterized by disturbed or unusual thinking, loss of interest in life, and intense or inappropriate emotions. It is also employed for the continuous treatment of individuals with bipolar I disorder, marked by episodes of depression, mania, and other abnormal moods.
Pharmacological Classification and Mechanism:
Abilify Maintena belongs to the class of atypical antipsychotics and functions by altering the activity of specific natural substances in the brain.
Administration and Frequency:
Abilify Maintena is an extended-release injectable suspension of aripiprazole, requiring administration only once a month.
Warnings and Precautions:
Abilify Maintena is not sanctioned for use in older adults experiencing dementia-related psychotic conditions, as aripiprazole may elevate the risk of death in this population. Individuals allergic to aripiprazole should not undergo Abilify Maintena treatment. Before commencement, it is crucial to inform the doctor of any difficulties with injections, heart conditions, blood pressure issues, diabetes, seizures, cholesterol abnormalities, dehydration, or low white blood cell counts. The use of antipsychotic medicine during the last trimester of pregnancy may lead to complications in newborns.
Administration Guidelines:
Abilify Maintena should be administered per the doctor’s instructions. For those unfamiliar with Abilify Maintena, oral aripiprazole may be required in tablet or liquid form before the initial injection. Continuing oral aripiprazole for 14 days post the first injection is typically necessary. Injections are given into a muscle every 4 to 8 weeks, with potential adjustments in dosage and schedule by the doctor. Regular blood sugar checks and other medical tests may be required.
Dosage Information:
Detailed dosage information for adults with schizophrenia or bipolar disorder is provided, including initial and maintenance doses. The duration between injections and potential dose adjustments for missed doses are outlined.
Missed Doses and Overdose:
Instructions for missed doses are specified based on the duration since the last injection. Overdose symptoms and appropriate actions are detailed.
Precautions During Treatment:
Guidance is provided on avoiding rapid changes in posture to prevent dizziness, refraining from driving or hazardous activities until the medicine’s effects are known, abstaining from alcohol consumption, and staying hydrated in hot conditions. Caution against excessive sun exposure and the importance of protective measures is emphasized.
Abilify Maintena Side Effects:
A comprehensive list of potential side effects is presented, ranging from allergic reactions to serious issues like uncontrolled muscle movements, difficulty swallowing, seizures, and high or low blood cell counts. Common side effects, such as restlessness, injection site pain, and drowsiness, are also mentioned.
Drug Interactions:
Information on potential drug interactions is provided, emphasizing the importance of informing the doctor about all current medications. Examples of drugs that may interact with Abilify Maintena are listed.
Ingredients:
Active and inactive ingredients in Abilify Maintena, including aripiprazole monohydrate, carboxymethyl cellulose sodium, mannitol, sodium phosphate monobasic monohydrate, and sodium hydroxide, are outlined.
